AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Jazz Pharmaceuticals to Participate in Wells Fargo Healthcare Conference
ByAinvest
Thursday, Aug 21, 2025 4:16 pm ET1min read
Jazz Pharmaceuticals will participate in the 2025 Wells Fargo Healthcare Conference, with management participating in a fireside chat on September 3, 2025. An audio webcast will be available on the company's website. Jazz Pharmaceuticals is a global biopharma company developing life-changing medicines for serious diseases with a diverse portfolio of marketed medicines and a growing pipeline of innovative therapeutics in oncology and neuroscience.
DUBLIN, Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced its participation in the 2025 Wells Fargo Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, September 3, 2025, at 6:30 a.m. PDT / 9:30 p.m. EDT / 2:30 p.m. IST. An audio webcast of the event will be available on the company's investor relations website at [Investor Jazz Pharmaceuticals](https://investor.jazzpharma.com/investors/events-presentations).Jazz Pharmaceuticals is a global biopharma company dedicated to developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options. The company's portfolio includes leading therapies for sleep disorders and epilepsy, and it has a growing pipeline of innovative therapeutics in oncology and neuroscience. Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with research and development laboratories, manufacturing facilities, and employees in multiple countries committed to serving patients worldwide [1].
In addition to its participation in the conference, Jazz Pharmaceuticals recently entered into an exclusive licensing agreement with Saniona. Under the terms of this agreement, Jazz will obtain exclusive worldwide rights to develop and commercialize SAN2355, a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator in preclinical development for epilepsy and other potential indications [2]. This collaboration leverages Jazz's expertise in epilepsy and neuroscience, positioning SAN2355 as a promising option for epilepsy and neurological conditions.
The fireside chat at the 2025 Wells Fargo Healthcare Conference will provide investors and financial professionals with an opportunity to hear directly from Jazz Pharmaceuticals' management about the company's latest developments, including its pipeline of innovative therapeutics and its strategic collaborations. The webcast will be archived on the company's website for 30 days following the event.
References:
[1] https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-the-2025-wells-fargo-healthcare-conference-302533954.html
[2] https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-enters-exclusive-licensing-agreement
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet